FR001400NLM4 - Common Stock

We assign a fundamental rating of **2** out of 10 to **ORP**. **ORP** was compared to 23 industry peers in the **Health Care Providers & Services** industry. **ORP** has a bad profitability rating. Also its financial health evaluation is rather negative. **ORP** is valied quite expensively at the moment, while it does show a decent growth rate.

In the past year **ORP** had a positive cash flow from operations.

Of the past 5 years **ORP** 4 years were profitable.

Each year in the past 5 years **ORP** had a positive operating cash flow.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -27.42% | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)-8.82%

ROA(5y)-4.57%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

The number of shares outstanding for **ORP** remains at a similar level compared to 5 years ago.

Based on the Altman-Z score of **-0.67**, we must say that **ORP** is in the distress zone and has some risk of bankruptcy.

The **Altman-Z score** of **ORP** (**-0.67**) is worse than **86.96%** of its industry peers.

The Debt to FCF ratio of **ORP** is **27.09**, which is on the high side as it means it would take **ORP**, **27.09** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | 27.09 | ||

Altman-Z | -0.67 |

ROIC/WACCN/A

WACC4.71%

The **Current ratio** of **ORP** (**0.17**) is worse than **95.65%** of its industry peers.

A Quick Ratio of **0.16** indicates that **ORP** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 0.17 | ||

Quick Ratio | 0.16 |

EPS 1Y (TTM)-6733.33%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-37.04%

Revenue 1Y (TTM)8.89%

Revenue growth 3Y7.76%

Revenue growth 5Y8.33%

Revenue growth Q2Q10.67%

Based on estimates for the next years, **ORP** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **26.00%** on average per year.

EPS Next Y12.98%

EPS Next 2Y32.97%

EPS Next 3Y26%

EPS Next 5YN/A

Revenue Next Year7.11%

Revenue Next 2Y6.48%

Revenue Next 3Y7.93%

Revenue Next 5YN/A

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

The **Price/Earnings Ratio** is negative for **ORP**. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **ORP**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 3.88 | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.97%

EPS Next 3Y26%

No dividends for **ORP**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**ORPEA**

EPA:ORP (4/22/2024, 1:22:59 PM)

**12.158**

**-0.09 (-0.75%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.94B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -27.42% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.32

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 0.17 | ||

Quick Ratio | 0.16 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-6733.33%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y12.98%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)8.89%

Revenue growth 3Y7.76%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y